Abstract:
The present invention provides process useful for the preparation of intermediates which are useful in the preparation of amino acids useful in preparing peptide receptor modulators, for example agonists or partial agonists of such peptide receptors. Such peptide receptor modulators include, for example glucagon like peptide-1 receptor modulators which are useful for the amelioration of the diabetic condition.

Description:
[0001]     This application claims priority to U.S. Provisional Patent Application Ser. No. 60/584,968, filed Jul. 2, 2004 of which is hereby incorporated by reference in its entirety. 
     
    
     FIELD OF THE INVENTION  
       [0002]     The present invention provides process useful for the preparation of intermediates which are useful in the preparation of amino acids useful in preparing peptide receptor modulators, for example agonists or partial agonists of such peptide receptors. Such peptide receptor modulators include, for example glucagon like peptide-1 receptor modulators which are useful for the amelioration of the diabetic condition.  
       BACKGROUND OF THE INVENTION  
       [0003]     It is desirable to develop peptide receptor modulators which may be useful for affecting the native activity of such a receptor and thus for affecting the biological pathways in which such a receptor is involved.  
         [0004]     For example, GLP-1 is an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism, and has been identified as a very potent and efficacious stimulator for insulin release. Therefore, it is desirable to develop modulators of peptide receptors, for example the GLP-1 receptor, which will affect the native activity of the receptor to effect a desired biological response.  
         [0005]     The present invention therefore provides a novel process for the preparation of intermediates useful in the preparation of amino acid which may be used in preparing peptide receptor modulators, for example GLP-1 receptor modulators, including agonists or partial agonists.  
       SUMMARY OF THE INVENTION  
       [0006]     In one aspect, the present invention is directed to a process for the preparation of a compound of Formula I:  
                         
 
 the process comprising the steps of: 
 
         [0007]     methylation of 3-ethylphenol to produce 3-ethylanisole;  
         [0008]     bromination of the 3-ethylanisole at a position para to a methoxy group to produce 4-bromo-3-ethyl anisole;  
         [0009]     conversion of the 4-bromo-3-ethyl anisole, the conversion comprising (a) reacting the 4-bromo-3-ethyl anisole with n-butyl lithium to produce the lithium salt of the corresponding anion of the 4-bromo-3-ethyl anisole; (b) reacting the lithium salt of the anion of the 4-bromo-3-ethyl anisole with triethyl borate; and (c) quenching with aqueous acid.  
         [0010]     In another aspect, the present invention is directed to a process for the preparation of a compound of Formula I:  
                         
 
 according to Scheme 1, as follows:  
                         
 
         [0011]     In another aspect, the present invention is directed to a process for the preparation of a compound of Formula II:  
                         
 
 the process comprising the steps of: 
 
         [0012]     methylation of 3-ethylphenol to produce 3-ethylanisole;  
         [0013]     bromination of the 3-ethylanisole at a position para to a methoxy group to produce 4-bromo-3-ethyl anisole;  
         [0014]     conversion of the 4-bromo-3-ethyl anisole, the conversion comprising (a) reacting the 4-bromo-3-ethyl anisole with n-butyl lithium to produce the lithium salt of the corresponding anion of the 4-bromo-3-ethyl anisole; (b) reacting the lithium salt of the anion of the 4-bromo-3-ethyl anisole with tri-n-butyl borate; (c) quenching with aqueous acid;  
         [0015]     reacting the resultant 2-ethyl-4-methoxy-phenylboronic acid with the triflic anhydride of a suitably protected tyrosine amino acid in the presence of a Palladium catalyst (Suzuki coupling); and  
         [0016]     removing the carboxyl protecting group from the resulting biphenyl amino acid to yield the amino-protected amino acid useful for incorporation into a peptide receptor modulator.  
         [0017]     In another aspect, the present invention is directed to a process for the preparation of a compound of Formula II:  
                         
 
 according to Scheme 2, as follows:  
                         
                         
 
     
    
     DETAILED DESCRIPTION OF THE INVENTION  
       [0018]     The present invention is directed to processes for the preparation of intermediates useful in the preparation of amino acids useful in preparing peptide receptor modulators, for example GLP-1 receptor modulators, including agonists or partial agonists.  
         [0019]     Such peptide receptor modulators may be useful for affecting the native activity of such a receptor and thus for affecting biological pathways in which such a receptor is involved. For example, GLP-1 is an important gut hormone with regulatory function in glucose metabolism and gastrointestinal secretion and metabolism, and has been identified as a very potent and efficacious stimulator for insulin release.  
         [0020]     Processes of the present invention are useful for preparing compounds of Formula I:  
                         
 
 which are useful in the preparation of amino acids of Formula II:  
                         
 
 Compounds of Formula II are useful in the preparation of peptide receptor modulators. 
 
       EXAMPLE 1  
     Synthesis of (2-Ethyl-4-methoxy)phenyl boronic acid  
       [0021]     (2-Ethyl-4-methoxy)phenyl boronic acid (Formula I) was prepared as follows, and as shown in Scheme 1: (1) methylation of 3-ethylphenol to produce 3-ethylanisole; (2) bromination of the 3-ethylanisole at a position para to a methoxy group to produce 4-bromo-3-ethyl anisole; (3) conversion of the 4-bromo-3-ethyl anisole, the conversion comprising (a) reacting the 4-bromo-3-ethyl anisole with n-butyl lithium to produce the lithium salt of the corresponding anion of the 4-bromo-3-ethyl anisole; (b) reacting the lithium salt of the anion of the 4-bromo-3-ethyl anisole with tri-n-butyl borate; and (c) quenching with aqueous acid.  
         [0022]     Specifically, To a mixture of 3-Ethylphenol (50 g, 0.4 mol, 98% pure, Fluka) and K 2 CO 3  (283 g, 2.05 mol) in dry acetone (500 ml) was added methyliodide (290 g, 2.05 mol). The reaction mixture was transferred to an autoclave and refluxed at 70° C. overnight. The reaction mixture was filtered through a Celite pad. The pad was washed with acetone and the combined filtrate and washes were concentrated. The product was dissolved in DCM, filtered and evaporated to dryness. Yield: 50 g, 90%, as a brown liquid.  
         [0023]     3-Ethylanisole (50 g, 0.3676 mol) and N-bromosuccinimide (72 g, 0.4 mol) in acetonitrile (1 L) were stirred for 8 hr under dark at RT. The reaction mixture was concentrated below 40° C. and the residue obtained was redissolved in CCl 4  and filtered. The filtrate was concentrated and the product was purified by fractional distillation. Yield: 35 g, 43%, as pale yellow liquid.  
         [0024]     A solution of 4-bromo-3-ethyl anisole (94 g, 0.437 mol) in THF (900 ml) was cooled to −78° C. n-Butyl lithium (249 ml, 0.55 mol) was added dropwise at the same temperature. Stirring was continued for 1 hr at −78° 0  C. Tri-n-butyl borate (177 ml, 0.655 mol) was added slowly at −78° C. The cooling bath was removed, the reaction mixture was allowed to warm to 0° C. and was quenched with 1.5 N hydrochloric acid at 0° C. The organic layer was separated. The aqueous layer was extracted with ethylacetate and the combined organic layers were washed with brine and concentrated. The residue obtained was stirred in pet-ether for 30 min. The solid obtained was filtered and dried under vacuum. Yield: 65 g, 82%, as a white solid.  
                         
 
       EXAMPLE 2  
     Amino Acid Synthesis  
       [0025]     The resultant (2-Ethyl-4-methoxy)phenyl boronic acid was used to prepare the amino acid of Formula II, according to Scheme 2:  
                         
 
                         
                         
 
       EXAMPLE III  
     Peptide Receptor Modulator Synthesis  
       [0026]     Peptide receptor modulators which may be thus produced by a compound of Formula II (Example III) includes a GLP-1 receptor modulator of Formula III: 
 
X aa1 —X aa2 —X aa3 —X aa4 —X aa5 —X aa6 —X aa7 —X aa8 —X aa9 —X aa10 —X aa11    III 
 
         [0027]     wherein,  
         [0028]     X aa1  is H;  
         [0029]     X aa2  is Aib;  
         [0030]     X aa3  is E;  
         [0031]     X aa4  is G;  
         [0032]     X aa5  is a T;  
         [0033]     X aa6  is L-α-Me-Phe(2-Fluoro);  
         [0034]     X aa7  is T;  
         [0035]     X aa8  is S;  
         [0036]     X aa9  is D;  
         [0037]     X aa10  is a compound of Formula II; and  
         [0038]     X aa11  is 4-(2′-methylphenyl)-3-pyridylalanine-NH2.  
         [0039]     Where the above amino acid abbreviations refer to those commonly understood in the art.  
         [0040]     Peptide receptor modulators produced from intermediate prepared by processes of the present invention may be prepared by any suitable manner recognized by one of skill in the art of peptide chemistry. For example, the peptides can be synthesized in a stepwise manner on an insoluble polymer support (also referred to as “resin”) starting from the C-terminus of the peptide. A synthesis is begun by appending the C-terminal amino acid of the peptide to the resin through formation of an amide or ester linkage. This allows the eventual release of the resulting peptide as a C-terminal amide or carboxylic acid, respectively. Alternatively, in cases where a C-terminal amino alcohol is present, the C-terminal residue may be attached to 2-Methoxy-4-alkoxybenzyl alcohol resin (SASRIN™, Bachem Bioscience, Inc., King of Prussia, Pa.) as described herein and, after completion of the peptide sequence assembly, the resulting peptide alcohol is released with LiBH4 in THF (see J. M. Stewart and J. D. Young, supra, p. 92). Also, a peptide synthesizer may be used, for example an Advanced Chemtech Multiple Peptide Synthesizer (MPS396) or an Applied Biosystems Inc. peptide synthesizer (ABI 433A).  
         [0041]     The following abbreviations may be used herein:  
                                                                 Ph = phenyl   DMF = N,N-dimethylformamide           Bn = benzyl   EtOAc = ethyl acetate           i-Bu = iso-butyl   THF = tetrahydrofuran           i-Pr = iso-propyl   TFA = trifluoroacetic acid           Me = methyl   NMP = N-methylpyrrolidone           Et = ethyl   DCM = dichloromethane           Pr = n-propyl   n-BuLi = n-butyllithium           Bu = n-butyl   Pd/C = palladium on carbon           TMS = trimethylsilyl   TEA = triethylamine           Et 2 O = diethyl ether   min = minute(s)           HOAc or AcOH = acetic   h or hr = hour(s)           acid   L = liter           MeCN = acetonitrile   mL or ml = milliliter               μl = microliter           g = gram(s)   rt = room temperature           mg = milligram(s)   sat or sat&#39;d = saturated           mol = mole(s)   aq. = aqueous           mmol = millimole(s)   mp = melting point           meq = milliequivalent   Bip = biphenylalanine                LiBH 4  = lithium borohydride           DIEA = Diisopropylethylamine           FMOC = fluorenylmethoxycarbonyl           Boc or BOC = tert-butoxycarbonyl           NBS = N-Bromosuccinimide           TLC = thin layer chromatography           HPLC = high performance liquid chromatography           LC/MS = high performance liquid chromatography/mass           spectrometry           MS or Mass Spec = mass spectrometry           NMR = nuclear magnetic resonance                      
 
         [0042]     One of skill in the art of peptide chemistry is aware that amino acid residues occur as both D and L isomers, and that the present invention includes the use of either or a mixture of isomers for amino acid residues incorporated in the synthesis of the peptides described herein.  
         [0043]     The present invention is not to be limited in scope by the specific embodiments described that are intended as single illustrations of individual aspects of the invention. Functionally equivalent methods and components in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.